Treatment of damaged nerve with pten inhibitor

Abstract

The present application discloses a method of growing or proliferating nerve cells by contacting the cells with phosphatase and tensin homolog (PTEN) lipid phosphatase inhibiting peptide.

What is claimed is: 
     
         1 . A method of regenerating nerve or attenuating degeneration of nerve at a site of nerve injury comprising administering at or an area near an injured nerve, a nerve regenerating or nerve degeneration attenuating amount of phosphatase and tensin homolog (PTEN) lipid phosphatase inhibiting peptide. 
     
     
         2 . The method according to  claim 1 , wherein the PTEN inhibitor peptide is modified PTEN peptide or fragment thereof in which phosphorylation site is modified such that a serine or threonine in the phosphorylation site is phosphorylated. 
     
     
         3 . The method according to  claim 1 , wherein the phosphorylated serine or threonine is located at position Thr-366, Ser-370, Ser-380, Thr-382, Thr-383 or Ser-385. 
     
     
         4 . The method according to  claim 1 , wherein the phosphorylated serine or threonine is located at position Ser-370, Ser-380 and/or Ser-385. 
     
     
         5 . The method according to  claim 3 , wherein the phosphorylated serine or threonine is located at position Ser-370, Ser-380 and Ser-385. 
     
     
         6 . The method according to  claim 3 , wherein the phosphorylated serine or threonine is located at position Ser-380 and Ser-385. 
     
     
         7 . The method according to  claim 1 , wherein the peptide is a fragment of a peptide of phosphorylation site and/or PDZ domain binding motif. 
     
     
         8 . The method according to  claim 1 , wherein the peptide further comprises a peptide transfer domain (PTD). 
     
     
         9 . The method according to  claim 1 , wherein the nerve injury is in the central nervous system. 
     
     
         10 . A peptide which inhibits phosphatase and tensin homolog (PTEN) lipid phosphatase activity. 
     
     
         11 . The peptide according to  claim 10 , wherein the peptide is a PTEN peptide or fragment thereof in which phosphorylation site is modified such that a serine or threonine in the phosphorylation site is phosphorylated. 
     
     
         12 . The peptide according to  claim 11 , wherein the phosphorylated serine or threonine is located at position Thr-366, Ser-370, Ser-380, Thr-382, Thr-383 or Ser-385. 
     
     
         13 . The peptide according to  claim 12 , wherein the phosphorylated serine or threonine is located at position Ser-370, Ser-380 and/or Ser-385. 
     
     
         14 . The peptide according to  claim 13 , wherein the phosphorylated serine or threonine is located at position Ser-370, Ser-380 and Ser-385. 
     
     
         15 . The peptide according to  claim 13 , wherein the phosphorylated serine or threonine is located at position Ser-380 and Ser-385. 
     
     
         16 . The peptide according to  claim 11 , wherein the peptide is a fragment of a peptide of phosphorylation site and/or PDZ domain binding motif. 
     
     
         17 . The peptide according to  claim 11 , wherein the peptide further comprises a peptide transfer domain (PTD). 
     
     
         18 . A method of growing, proliferating or enhancing cell activity of a nerve cell comprising contacting the nerve cell with a phosphatase and tensin homolog (PTEN) lipid phosphatase inhibiting peptide.